When initiating chronic suppressive therapy with fosfomycin, is a negative urinalysis and urine culture with sensitivity required before starting treatment?

Fosfomycin for Chronic Suppressive Therapy: Pre-Treatment Testing Requirements

You should obtain urinalysis and urine culture with sensitivity testing before initiating chronic suppressive therapy with fosfomycin, even though this is not explicitly required by FDA labeling for acute treatment. This recommendation is based on guideline-level evidence for recurrent UTI management and the fundamental principle that suppressive therapy requires documented infection and antimicrobial susceptibility data.

Rationale for Pre-Treatment Testing

The 2025 AUA/CUA/SUFU guidelines explicitly state that clinicians should obtain urinalysis, urine culture and sensitivity with each symptomatic acute cystitis episode prior to initiating treatment in patients with recurrent UTIs 1. While these guidelines address acute episodes rather than suppressive therapy specifically, the principle is even more critical when planning long-term antibiotic use because:

• Microbiological confirmation is essential before committing a patient to chronic antibiotic exposure
• Susceptibility testing ensures fosfomycin will be effective against the patient's specific uropathogen
• Baseline documentation allows monitoring for treatment failure or resistance development
• Negative cultures may indicate alternative diagnoses that would not benefit from suppressive antibiotics

Key Testing Components

Before starting fosfomycin suppression, obtain:

1. Urinalysis: A negative urinalysis (negative nitrites and <5 WBC/hpf) has 92.2% specificity and 97.4% positive predictive value for ruling out UTI 1. If negative, reconsider whether suppressive therapy is indicated.

2. Urine culture with sensitivity: This confirms the presence of a uropathogen and documents fosfomycin susceptibility. The 2024 EAU guidelines emphasize that antimicrobial resistance is more likely in complicated UTIs, making susceptibility testing mandatory 2.

Important Caveats

Timing Considerations

• Avoid testing immediately after recent antibiotic use: Fluoroquinolones can suppress bacterial growth in urine cultures for up to 10 days after discontinuation 3, and similar effects may occur with other antibiotics 4
• If the patient recently completed antibiotics, wait at least 7-10 days before obtaining cultures to avoid false-negative results

FDA Labeling Context

The FDA label for oral fosfomycin states that "urine specimens for culture and susceptibility testing should be obtained before and after completion of therapy" 5. While this refers to acute single-dose treatment, the principle applies even more strongly to chronic suppressive use, which represents off-label prescribing requiring heightened clinical justification.

Clinical Pitfall

Do not rely on symptoms alone to justify suppressive therapy. Research demonstrates that 90% of patients with chronic painful lower urinary tract symptoms and pyuria who stopped long-term antibiotics experienced deterioration 6, but this does not justify starting suppression without documented infection—it only supports continuation in those already established on effective therapy.

Algorithm for Initiating Fosfomycin Suppression

1. Confirm recurrent UTI pattern: Document ≥2 culture-proven infections in 6 months or ≥3 in 12 months
2. Ensure adequate washout: Wait 7-10 days after any recent antibiotic use
3. Obtain fresh urinalysis: If negative (<5 WBC/hpf, negative nitrites), reconsider diagnosis
4. Send urine culture with fosfomycin sensitivity: Do not start suppression until results confirm susceptible organism
5. Rule out anatomic/functional abnormalities: Per guidelines, perform pelvic examination and consider imaging 1
6. Initiate suppression only after confirming: Positive culture + fosfomycin susceptibility + no correctable underlying factors

Bottom line: A negative urinalysis and culture are not required—but a positive culture with documented fosfomycin susceptibility IS required before starting chronic suppressive therapy. Starting empiric long-term antibiotics without microbiological confirmation contradicts antimicrobial stewardship principles and risks treating non-infectious conditions with unnecessary chronic antibiotic exposure.